Company Mabion S.A.

Equities

MAB

PLMBION00016

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Mabion S.A.

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Warsaw S.E. Other stock markets 11:55:56 2024-04-24 am EDT			5-day change	1st Jan Change
16.64 ^PLN	-1.77%		-5.45%	-8.32%

Apr. 16	Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Number of employees: 244

PLN in Million	2022	Weight	Delta
Biological Drugs 100.0 %	164	100.0 %	-

PLN in Million	2022	Weight	Delta
Poland 100.0 %	164	100.0 %	-

Managers	Title	Age	Since
Krzysztof Kaczmarczyk CEO	Chief Executive Officer	-	-
Grzegorz Mariusz Grabowicz DFI	Director of Finance/CFO	50	18-12-31
Slawomir Jaros CTO	Chief Tech/Sci/R&D Officer	-	09-10-28
Katarzyna Kutera-Wasiak AUD	Comptroller/Controller/Auditor	-	-
Adam Pietruszkiewicz PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Krzysztof Kaczmarczyk CEO	Chief Executive Officer	-	-
Robert Leszek Konski CHM	Chairman	58	17-06-13
Józef Antoni Banach BRD	Director/Board Member	51	-
Adam Pietruszkiewicz PRN	Corporate Officer/Principal	-	-
Slawomir Kosciak BRD	Director/Board Member	40	21-02-22
David John James BRD	Director/Board Member	-	-
Wojciech Wosko BRD	Director/Board Member	-	21-02-22
Zofia Szewczuk BRD	Director/Board Member	-	21-08-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	16,162,326	10,295,878 ( 63.70 %)	0	63.70 %

Name	Equities	%	Valuation
Generali PTE SA 2.227 %	359,992	2.227 %	1 M zł
Investors TFI SA 1.222 %	197,503	1.222 %	807 297 zł
UNIQA PTE SA 0.6018 %	97,271	0.6018 %	397 597 zł
Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych SA 0.4088 %	66,076	0.4088 %	270 087 zł
ESALIENS TFI SA 0.3466 %	56,023	0.3466 %	228 995 zł
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA 0.2635 %	42,581	0.2635 %	174 051 zł
AgioFunds TFI SA 0.1123 %	18,150	0.1123 %	74 188 zł
MetLife TFI SA 0.0538 %	8,702	0.0538 %	35 570 zł
BNP Paribas Polska TFI SA 0.0116 %	1,881	0.0116 %	7 689 zł
IPOPEMA TFI SA 0.0103 %	1,672	0.0103 %	6 834 zł

Mabion SA

ul. gen. Mariana Langiewicza 60

95-050, Konstantynów Lódzki

+48 42 207 7890

http://www.mabion.eu

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

16.64 PLN

Average target price

16.17 PLN

Spread / Average Target

-2.84%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MABION S.A.	-8.32%	66.36M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs